摘要
目的对比小儿肺热咳喘颗粒与磷酸奥司他韦颗粒治疗儿童流行性感冒的成本-效果,以评估两种药物的经济性。方法基于卫生体系视角,构建决策树模型进行成本-效果分析。通过单因素敏感性分析和概率敏感性分析,评估各参数变动对研究结果的影响。结果小儿肺热咳喘颗粒与磷酸奥司他韦颗粒的增量成本-效果比为96.8元。概率敏感性分析显示,基于5 d的治疗周期,当支付意愿值>260元时,小儿肺热咳喘颗粒成为更具经济性的选择。单因素敏感性分析显示,在影响增量成本-效果比的各种因素中,磷酸奥司他韦颗粒的价格为最敏感因素。结论当支付意愿值>260元时,小儿肺热咳喘颗粒治疗儿童流行性感冒具有经济学优势。
Objective To compare the cost-effectiveness of Xiaoer Feire Kechuan granules(XFK)with that of oseltamivir phosphate granules in the treatment of pediatric influenza to evaluate their economic value.Methods A decision tree model was developed from the perspective of the healthcare system to conduct a costeffectiveness analysis.Univariate and probabilistic sensitivity analyses were performed to evaluate how parameter variations influenced the study outcomes.Results The incremental cost-effectiveness ratio(ICER)of XFK compared to oseltamivir phosphate granules was¥96.8.The probabilistic sensitivity analysis results showed that over a 5-day treatment cycle,when the willingness-to-pay(WTP)exceeded¥260,XFK became the more costeffective option.Univariate sensitivity analysis indicated that the price of oseltamivir phosphate granules was the most sensitive factor among all the factors of ICER.Conclusion When the willingness-to-pay is over¥260,XFK demonstrates a cost-effective advantage in the treatment of pediatric influenza.
作者
邵尉
梅晰凡
王峰
于飞
尹笋君
韩丹
SHAO Wei;MEI Xifan;WANG Feng;YU Fei;YIN Sunjun;HAN Dan(Liaoning Vocational College of Medicine,Liaoning Institute of Basic Medical Sciences,Shenyang 110101,China;The 920th Hospital of the Joint Logistic Support Force of PLA,Kunming 650032,China;Naval Medical University,Shanghai 200433,China)
出处
《中国中西医结合儿科学》
2025年第5期418-423,共6页
Chinese Pediatrics of Integrated Traditional and Western Medicine
基金
2024年度沈阳市哲学社会科学课题(SYSK2024-01-130)。
